We'd be surprised if TG Therapeutics, Inc. (NASDAQ:TGTX) shareholders haven't noticed that the Independent Director, Yann Echelard, recently sold US$490k worth of stock at US$24.48 per share. On the bright side, that sale was only 8.2% of their holding, so we doubt it's very meaningful, on its own.

The Last 12 Months Of Insider Transactions At TG Therapeutics

Over the last year, we can see that the biggest insider sale was by the CFO, Corporate Secretary & Treasurer, Sean Power, for US$809k worth of shares, at about US$16.91 per share. That means that an insider was selling shares at slightly below the current price (US$28.81). As a general rule we consider it to be discouraging when insiders are selling below the current price, because it suggests they were happy with a lower valuation. Please do note, however, that sellers may have a variety of reasons for selling, so we don't know for sure what they think of the stock price. It is worth noting that this sale was only 6.6% of Sean Power's holding.

TG Therapeutics insiders didn't buy any shares over the last year. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. (Hint: Most of them are flying under the radar).

Insider Ownership

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. I reckon it's a good sign if insiders own a significant number of shares in the company. TG Therapeutics insiders own 7.0% of the company, currently worth about US$278m based on the recent share price. I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders.

So What Does This Data Suggest About TG Therapeutics Insiders?

An insider hasn't bought TG Therapeutics stock in the last three months, but there was some selling. And there weren't any purchases to give us comfort, over the last year. The company boasts high insider ownership, but we're a little hesitant, given the history of share sales. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing TG Therapeutics. Every company has risks, and we've spotted 1 warning sign for TG Therapeutics you should know about.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.